Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1314

1.

CSF α-synuclein correlates with CSF neurogranin in late-life depression.

Bruno D, Reichert Plaska C, Clark DPA, Zetterberg H, Blennow K, Verbeek MM, Pomara N.

Int J Neurosci. 2020 Mar 31:1-5. doi: 10.1080/00207454.2020.1744596. [Epub ahead of print]

PMID:
32228205
2.

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease.

Dhiman K, Gupta VB, Villemagne VL, Eratne D, Graham PL, Fowler C, Bourgeat P, Li QX, Collins S, Bush AI, Rowe CC, Masters CL, Ames D, Hone E, Blennow K, Zetterberg H, Martins RN.

Alzheimers Dement (Amst). 2020 Feb 27;12(1):e12005. doi: 10.1002/dad2.12005. eCollection 2020.

3.

The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial.

Abdullah L, Crawford F, Tsolaki M, Börjesson-Hanson A, Olde Rikkert M, Pasquier F, Wallin A, Kennelly S, Ait-Ghezala G, Paris D, Hendrix S, Blennow K, Lawlor B, Mullan M.

Front Neurol. 2020 Mar 6;11:149. doi: 10.3389/fneur.2020.00149. eCollection 2020.

4.

Cardiac Surgery is Associated with Biomarker Evidence of Neuronal Damage.

Alifier M, Olsson B, Andreasson U, Cullen NC, Czyżewska J, Jakubów P, Sieśkiewicz A, Stasiak-Barmuta A, Hirnle T, Kornhuber J, Zetterberg H, Lewczuk P, Blennow K.

J Alzheimers Dis. 2020 Mar 11. doi: 10.3233/JAD-191165. [Epub ahead of print]

PMID:
32176641
5.

APOE-ε4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks.

Cacciaglia R, Molinuevo JL, Falcón C, Arenaza-Urquijo EM, Sánchez-Benavides G, Brugulat-Serrat A, Blennow K, Zetterberg H, Gispert JD; ALFA study.

Cereb Cortex. 2020 Mar 12. pii: bhaa034. doi: 10.1093/cercor/bhaa034. [Epub ahead of print]

PMID:
32163130
6.

[Alzheimer's disease - the most common cause of dementia].

Bogdanovic N, Hansson O, Zetterberg H, Basun H, Ingelsson M, Lannfelt L, Blennow K.

Lakartidningen. 2020 Mar 9;117. pii: FZHM. Swedish.

7.

Low CSF/serum ratio of free T4 is associated with decreased quality of life in mild hypothyroidism - A pilot study.

Funkquist A, Bengtsson A, Johansson PM, Svensson J, Bjellerup P, Blennow K, Wandt B, Sjöberg S.

J Clin Transl Endocrinol. 2020 Feb 4;19:100218. doi: 10.1016/j.jcte.2020.100218. eCollection 2020 Mar.

8.

Tauopathy-Associated Tau Fragment Ending at Amino Acid 224 Is Generated by Calpain-2 Cleavage.

Cicognola C, Satir TM, Brinkmalm G, Matečko-Burmann I, Agholme L, Bergström P, Becker B, Zetterberg H, Blennow K, Höglund K.

J Alzheimers Dis. 2020 Mar 2. doi: 10.3233/JAD-191130. [Epub ahead of print]

PMID:
32144989
9.

Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults.

Kresge HA, Liu D, Gupta DK, Moore EE, Osborn KE, Acosta LMY, Bell SP, Pechman KR, Gifford KA, Mendes LA, Wang TJ, Blennow K, Zetterberg H, Hohman TJ, Jefferson AL.

J Alzheimers Dis. 2020 Mar 2. doi: 10.3233/JAD-190813. [Epub ahead of print]

PMID:
32144980
10.

Self-reported Sleep Problems Related to Amyloid Deposition in Cortical Regions with High HOMER1 Gene Expression.

Fjell AM, Sederevicius D, Sneve MH, de Lange AG, Bråthen AC, Idland AV, Watne LO, Wang Y, Reinbold C, Dobricic V, Kilpert F, Blennow K, Zetterbergj H, Hong S, Bertram L, Walhovd KB; Alzheimer’s Disease Neuroimaging Initiative.

Cereb Cortex. 2019 Nov 11. pii: bhz228. doi: 10.1093/cercor/bhz228. [Epub ahead of print]

PMID:
32142100
11.

Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.

Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, Bourakova V, Cobigo Y, Heuer H, Spina S, VandeVrede L, Chai X, Proctor NK, Airey DC, Shcherbinin S, Duggan Evans C, Sims JR, Zetterberg H, Blennow K, Karydas AM, Teunissen CE, Kramer JH, Grinberg LT, Seeley WW, Rosen H, Boeve BF, Miller BL, Rabinovici GD, Dage JL, Rojas JC, Boxer AL; Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators.

Nat Med. 2020 Mar;26(3):387-397. doi: 10.1038/s41591-020-0762-2. Epub 2020 Mar 2.

PMID:
32123386
12.

Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.

Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H, Blennow K, Reiman EM, Stomrud E, Dage JL, Hansson O.

Nat Med. 2020 Mar;26(3):379-386. doi: 10.1038/s41591-020-0755-1. Epub 2020 Mar 2.

PMID:
32123385
13.

The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease.

Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM; Synaptic Health Endpoints Working Group.

Alzheimers Res Ther. 2020 Mar 2;12(1):21. doi: 10.1186/s13195-020-00588-4. Review.

14.

Author Correction: Accelerated neuronal and synaptic maturation by BrainPhys medium increases Aβ secretion and alters Aβ peptide ratios from iPSC-derived cortical neurons.

Satir TM, Nazir FH, Vizlin-Hodzic D, Hardselius E, Blennow K, Wray S, Zetterberg H, Agholme L, Bergström P.

Sci Rep. 2020 Feb 28;10(1):3993. doi: 10.1038/s41598-020-61008-z.

15.

Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg.

Obrocki P, Khatun A, Ness D, Senkevich K, Hanrieder J, Capraro F, Mattsson N, Andreasson U, Portelius E, Ashton NJ, Blennow K, Schöll M, Paterson RW, Schott JM, Zetterberg H.

Alzheimers Res Ther. 2020 Feb 28;12(1):20. doi: 10.1186/s13195-020-00586-6. Review.

16.

Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure.

Dickstein DL, De Gasperi R, Gama Sosa MA, Perez-Garcia G, Short JA, Sosa H, Perez GM, Tschiffely AE, Dams-O'Connor K, Pullman MY, Knesaurek K, Knutsen A, Pham DL, Soleimani L, Jordan BD, Gordon WA, Delman BN, Shumyatsky G, Shahim PP, DeKosky ST, Stone JR, Peskind E, Blennow K, Zetterberg H, Chance SA, Torso M, Kostakoglu L, Sano M, Hof PR, Ahlers ST, Gandy S, Elder GA.

Mol Psychiatry. 2020 Feb 25. doi: 10.1038/s41380-020-0674-z. [Epub ahead of print]

PMID:
32094584
17.

Association of brain network dynamics with plasma biomarkers in subjective memory complainers.

Chiesa PA, Houot M, Vergallo A, Cavedo E, Lista S, Potier MC, Zetterberg H, Blennow K, Vanmechelen E, De Vos A, Dubois B, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI).

Neurobiol Aging. 2020 Apr;88:83-90. doi: 10.1016/j.neurobiolaging.2019.12.017. Epub 2019 Dec 23.

PMID:
32087948
18.

Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method.

Korecka M, Figurski MJ, Landau SM, Brylska M, Alexander J, Blennow K, Zetterberg H, Jagust WJ, Trojanowski JQ, Shaw LM; Alzheimer’s Disease Neuroimaging Initiative.

Clin Chem. 2020 Apr 1;66(4):587-597. doi: 10.1093/clinchem/hvaa012.

PMID:
32087019
19.

Genome-wide study of immune biomarkers in cerebrospinal fluid and serum from patients with bipolar disorder and controls.

Zhang R, Song J, Isgren A, Jakobsson J, Blennow K, Sellgren CM, Zetterberg H, Bergen SE, Landén M.

Transl Psychiatry. 2020 Feb 5;10(1):58. doi: 10.1038/s41398-020-0737-6.

20.

Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases.

Minta K, Brinkmalm G, Janelidze S, Sjödin S, Portelius E, Stomrud E, Zetterberg H, Blennow K, Hansson O, Andreasson U.

Alzheimers Res Ther. 2020 Feb 13;12(1):19. doi: 10.1186/s13195-020-00585-7.

21.

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia.

Llorens F, Hermann P, Villar-Piqué A, Diaz-Lucena D, Nägga K, Hansson O, Santana I, Schmitz M, Schmidt C, Varges D, Goebel S, Dumurgier J, Zetterberg H, Blennow K, Paquet C, Baldeiras I, Ferrer I, Zerr I.

Nat Commun. 2020 Jan 30;11(1):619. doi: 10.1038/s41467-020-14373-2.

22.

Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2020 Jan 18. doi: 10.1007/s00401-019-02107-8. [Epub ahead of print]

PMID:
31955222
23.

Accelerated neuronal and synaptic maturation by BrainPhys medium increases Aβ secretion and alters Aβ peptide ratios from iPSC-derived cortical neurons.

Satir TM, Nazir FH, Vizlin-Hodzic D, Hardselius E, Blennow K, Wray S, Zetterberg H, Agholme L, Bergström P.

Sci Rep. 2020 Jan 17;10(1):601. doi: 10.1038/s41598-020-57516-7. Erratum in: Sci Rep. 2020 Feb 28;10(1):3993.

24.

Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures.

Falgàs N, Ruiz-Peris M, Pérez-Millan A, Sala-Llonch R, Antonell A, Balasa M, Borrego-Écija S, Ramos-Campoy O, Augé JM, Castellví M, Tort-Merino A, Olives J, Fernández-Villullas G, Blennow K, Zetterberg H, Bargalló N, Lladó A, Sánchez-Valle R.

Hum Brain Mapp. 2020 Jan 16. doi: 10.1002/hbm.24925. [Epub ahead of print]

PMID:
31944489
25.

Complement component 3 levels in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder.

Pillai A, Bruno D, Nierenberg J, Pandya C, Feng T, Reichert C, Ramos-Cejudo J, Osorio R, Zetterberg H, Blennow K, Pomara N.

Biomark Neuropsychiatry. 2019 Dec;1. pii: 100007. doi: 10.1016/j.bionps.2019.100007. Epub 2019 Nov 13.

26.

Neuroinflammatory markers associate with cognitive decline after major surgery: Findings of an explorative study.

Danielson M, Wiklund A, Granath F, Blennow K, Mkrtchian S, Nellgård B, Oras J, Jonsson Fagerlund M, Granström A, Schening A, Rasmussen LS, Erlandsson Harris H, Zetterberg H, Ricksten SE, Eriksson LI.

Ann Neurol. 2020 Mar;87(3):370-382. doi: 10.1002/ana.25678. Epub 2020 Jan 25.

PMID:
31930549
27.

Cerebrospinal Fluid Levels of Interleukin-8 in Delirium, Dementia, and Cognitively Healthy Patients.

Sajjad MU, Blennow K, Knapskog AB, Idland AV, Chaudhry FA, Wyller TB, Zetterberg H, Watne LO.

J Alzheimers Dis. 2020;73(4):1363-1372. doi: 10.3233/JAD-190941.

PMID:
31929159
28.

Circulating levels of vascular endothelial growth factor and post-stroke long-term functional outcome.

Åberg ND, Wall A, Anger O, Jood K, Andreasson U, Blennow K, Zetterberg H, Isgaard J, Jern C, Svensson J.

Acta Neurol Scand. 2020 Jan 9. doi: 10.1111/ane.13219. [Epub ahead of print]

PMID:
31919840
29.
30.

Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men.

Benedict C, Blennow K, Zetterberg H, Cedernaes J.

Neurology. 2020 Mar 17;94(11):e1181-e1189. doi: 10.1212/WNL.0000000000008866. Epub 2020 Jan 8.

PMID:
31915189
31.

Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings.

Vermunt L, Muniz-Terrera G, Ter Meulen L, Veal C, Blennow K, Campbell A, Carrié I, Delrieu J, Fauria K, Huesa Rodríguez G, Ingala S, Jenkins N, Molinuevo JL, Ousset PJ, Porteous D, Prins ND, Solomon A, Tom BD, Zetterberg H, Zwan M, Ritchie CW, Scheltens P, Luscan G, Brookes AJ, Visser PJ; IMI-EPAD collaborators.

Alzheimers Res Ther. 2020 Jan 6;12(1):8. doi: 10.1186/s13195-019-0576-y.

32.

Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease.

Parbo P, Madsen LS, Ismail R, Zetterberg H, Blennow K, Eskildsen SF, Vorup-Jensen T, Brooks DJ.

Alzheimers Res Ther. 2020 Jan 2;12(1):3. doi: 10.1186/s13195-019-0574-0.

33.

A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort.

Stamate D, Kim M, Proitsi P, Westwood S, Baird A, Nevado-Holgado A, Hye A, Bos I, Vos SJB, Vandenberghe R, Teunissen CE, Kate MT, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck E, Engelborghs S, Sleegers K, Bordet R, Ramit L, Kettunen P, Tsolaki M, Verhey F, Alcolea D, Lléo A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Legido-Quigley C.

Alzheimers Dement (N Y). 2019 Dec 18;5:933-938. doi: 10.1016/j.trci.2019.11.001. eCollection 2019.

34.

Glycan biomarkers for Alzheimer disease correlate with T-tau and P-tau in cerebrospinal fluid in subjective cognitive impairment.

Schedin-Weiss S, Gaunitz S, Sui P, Chen Q, Haslam SM, Blennow K, Winblad B, Dell A, Tjernberg LO.

FEBS J. 2019 Dec 30. doi: 10.1111/febs.15197. [Epub ahead of print]

PMID:
31889402
35.

Longitudinal change in regional brain volumes with exposure to repetitive head impacts.

Bernick C, Shan G, Zetterberg H, Banks S, Mishra VR, Bekris L, Leverenz JB, Blennow K.

Neurology. 2020 Jan 21;94(3):e232-e240. doi: 10.1212/WNL.0000000000008817. Epub 2019 Dec 23.

PMID:
31871218
36.

Neurofilaments in blood is a new promising preclinical biomarker for the screening of natural scrapie in sheep.

Zetterberg H, Bozzetta E, Favole A, Corona C, Cavarretta MC, Ingravalle F, Blennow K, Pocchiari M, Meloni D.

PLoS One. 2019 Dec 19;14(12):e0226697. doi: 10.1371/journal.pone.0226697. eCollection 2019.

37.

CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia.

Clarke MTM, Brinkmalm A, Foiani MS, Woollacott IOC, Heller C, Heslegrave A, Keshavan A, Fox NC, Schott JM, Warren JD, Blennow K, Zetterberg H, Rohrer JD.

Alzheimers Res Ther. 2019 Dec 17;11(1):105. doi: 10.1186/s13195-019-0564-2.

38.

An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead.

Simrén J, Ashton NJ, Blennow K, Zetterberg H.

Curr Opin Neurobiol. 2019 Dec 12;61:29-39. doi: 10.1016/j.conb.2019.11.019. [Epub ahead of print] Review.

PMID:
31838254
39.

Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders.

Hall S, Janelidze S, Zetterberg H, Brix B, Mattsson N, Surova Y, Blennow K, Hansson O.

Mov Disord. 2020 Mar;35(3):513-518. doi: 10.1002/mds.27950. Epub 2019 Dec 13.

PMID:
31837067
40.

Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays.

Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, Buck K, Wahl S, Eichenlaub U, Lifke V, Simon M, Trojanowski JQ, Hansson O.

Sci Rep. 2019 Dec 13;9(1):19024. doi: 10.1038/s41598-019-54204-z.

41.

Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology.

Blennow K, Chen C, Cicognola C, Wildsmith KR, Manser PT, Bohorquez SMS, Zhang Z, Xie B, Peng J, Hansson O, Kvartsberg H, Portelius E, Zetterberg H, Lashley T, Brinkmalm G, Kerchner GA, Weimer RM, Ye K, Höglund K.

Brain. 2020 Feb 1;143(2):650-660. doi: 10.1093/brain/awz346.

PMID:
31834365
42.

Salivary Biomarkers for Alzheimer's Disease and Related Disorders.

Ashton NJ, Ide M, Zetterberg H, Blennow K.

Neurol Ther. 2019 Dec;8(Suppl 2):83-94. doi: 10.1007/s40120-019-00168-1. Epub 2019 Dec 12. Review.

43.

Peripheral Biomarkers for Alzheimer's Disease: Update and Progress.

Sabbagh MN, Blennow K.

Neurol Ther. 2019 Dec;8(Suppl 2):33-36. doi: 10.1007/s40120-019-00171-6. Epub 2019 Dec 12. No abstract available.

44.

Repeated lumbar punctures within 3 days may affect CSF biomarker levels.

Olsson M, Ärlig J, Hedner J, Blennow K, Zetterberg H.

Fluids Barriers CNS. 2019 Dec 13;16(1):37. doi: 10.1186/s12987-019-0157-2.

45.

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.

Hermansson L, Yilmaz A, Price RW, Nilsson S, McCallister S, Makadzange T, Das M, Zetterberg H, Blennow K, Gisslen M.

PLoS One. 2019 Dec 11;14(12):e0226276. doi: 10.1371/journal.pone.0226276. eCollection 2019.

46.

CSF sTREM2 and Tau Work Together in Predicting Increased Temporal Lobe Atrophy in Older Adults.

Halaas NB, Henjum K, Blennow K, Dakhil S, Idland AV, Nilsson LN, Sederevicius D, Vidal-Piñeiro D, Walhovd KB, Wyller TB, Zetterberg H, Watne LO, Fjell AM.

Cereb Cortex. 2019 Dec 8. pii: bhz240. doi: 10.1093/cercor/bhz240. [Epub ahead of print]

PMID:
31812991
47.

Special Issue CCA for the proceedings of the 2nd symposium of the Society of CSF analysis and Clinical Neurochemistry.

Teunissen C, Parnetti L, Blennow K, Otto M.

Clin Chim Acta. 2020 Mar;502:199-200. doi: 10.1016/j.cca.2019.12.005. Epub 2019 Dec 6. No abstract available.

PMID:
31812757
48.

Postoperative delirium is associated with increased plasma neurofilament light.

Casey CP, Lindroth H, Mohanty R, Farahbakhsh Z, Ballweg T, Twadell S, Miller S, Krause B, Prabhakaran V, Blennow K, Zetterberg H, Sanders RD.

Brain. 2020 Jan 1;143(1):47-54. doi: 10.1093/brain/awz354.

PMID:
31802104
49.

Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease.

Cavedo E, Lista S, Houot M, Vergallo A, Grothe MJ, Teipel S, Zetterberg H, Blennow K, Habert MO, Potier MC, Dubois B, Hampel H; INSIGHT-preAD Study Group and the Alzheimer Precision Medicine Initiative.

Neurology. 2020 Jan 7;94(1):e30-e41. doi: 10.1212/WNL.0000000000008696. Epub 2019 Dec 4.

PMID:
31801830
50.

Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.

Ashton NJ, Suárez-Calvet M, Heslegrave A, Hye A, Razquin C, Pastor P, Sanchez-Valle R, Molinuevo JL, Visser PJ, Blennow K, Hodges AK, Zetterberg H.

Alzheimers Res Ther. 2019 Nov 28;11(1):94. doi: 10.1186/s13195-019-0545-5.

Supplemental Content

Loading ...
Support Center